Modular Medical Inc. (MODD)
NASDAQ (CM) NASDAQ (CM) Primary 
Modular Medical Announces Licensing and Partnership Agreement With Nudge BG
-Modular Medical will collaborate with Nudge BG to bring to market an adaptive full closed loop Automated Insulin Delivery system that does not require mealtime announcements -Effort will be led be Nudge BG founder and noted AID expert, Lane Desborough SAN DIEGO, CA / ACCESSWIRE / December 19, 2024 / Modular Medical, Inc. (Nasdaq:MODD) ("Modular Medical" or the "Company"), an insulin delivery technology company with the first FDA-cleared patch pump designed specifically to meet the needs of "almost-pumpers" with its user-friendly and affordable design, announced a licensing and partnership agreement with Nudge BG. "We are very excited to partner with Modular Medical to bring the next generation of automated insulin delivery ("AID") to the marketplace," said Lane Desborough, CEO of Nudge BG.
Modular Medical Announces Pricing of $8.2 Million Public Offering
SAN DIEGO, CA / ACCESSWIRE / November 21, 2024 / Modular Medical, Inc. (Nasdaq:MODD) ("Modular Medical" or the "Company"), an insulin delivery technology company with the first FDA-cleared patch pump designed specifically to target all adult "almost-pumpers" with its user-friendly and affordable design, today announced that it has priced an underwritten public offering (the "offering") of 5,450,573 shares of its common stock. The offering was led by existing institutional investors, including Manchester Explorer, L.P.
Modular Medical Announces Proposed Public Offering
SAN DIEGO, CA / ACCESSWIRE / November 21, 2024 / Modular Medical, Inc. (NASDAQ:MODD) ("Modular Medical"), an insulin delivery technology company with the first FDA-cleared patch pump designed specifically to target all adult "almost-pumpers" with its user-friendly and affordable design, today announced that it has commenced an underwritten public offering (the "offering") of shares of its common stock (or pre-funded warrants to purchase shares of its common stock in lieu thereof). Modular Medical also has granted the underwriter a 30-day option to purchase up to an additional 15% of the aggregate number of shares of its common stock (or pre-funded warrants) sold in the offering.
Modular Medical Proudly Sponsors the Inaugural Achieving Diabetes Equity in Practice Today (ADEPT) Conference
SAN DIEGO, CA / ACCESSWIRE / November 11, 2024 / Modular Medical, Inc. (NASDAQ:MODD) ("Modular Medical" or the "Company"), an insulin delivery technology company with the first FDA-cleared patch pump designed specifically to target all adult "almost-pumpers" with its user-friendly and affordable design, today announced that it is a Gold sponsor of the upcoming, first annual Achieving Diabetes Equity in Practice Today (ADEPT) Conference taking place at the Chicago Marriott Downtown on November 12 and 13,2024. The ADEPT Conference, which is the result of a collaborative effort between the American Diabetes Association and the T1D Exchange, will bring together key stakeholders focused on achieving health equity in type 1 and type 2 diabetes.
Modular Medical Announces Issuance of U.S. Patent Covering Key Aspects of Core Pumping Technology
Allowed claims cover major features of pumping mechanism in FDA-cleared MODD1 product SAN DIEGO, CA / ACCESSWIRE / September 18, 2024 / Modular Medical, Inc. (NASDAQ:MODD) ("Modular Medical" or the "Company"), an insulin delivery technology company with the first FDA-cleared patch pump designed specifically to target all adult "almost-pumpers" thanks to its user-friendly and affordable design, announced the issuance of U.S. Divisional Patent Application No. 17/968,599.
Modular Medical Announces Conference Call to Discuss FDA Clearance of the MODD1 Insulin Pump
SAN DIEGO, CA / ACCESSWIRE / September 4, 2024 / Modular Medical, Inc. (the "Company" or "Modular Medical") (NASDAQ:MODD), an insulin delivery system technology company preparing to launch a market expansion product with a more accessible, easier to prescribe, and easier to pay for and live with technology, today announced it will hold a conference call and webcast tomorrow, Thursday, September 5, 2024, at 8:30 a.m. Eastern Time to discuss the U.
Modular Medical Announces FDA Clearance of the MODD1 Insulin Pump
MODD1 is a patch pump for ALL adults with Type 1 and Type 2 diabetes Designed to be simpler and more affordable to expand access to diabetes technology for previously underserved communities Commercial availability expected in early 2025 SAN DIEGO, CA / ACCESSWIRE / September 4, 2024 / Modular Medical, Inc. (the "Company" or "Modular Medical") (NASDAQ:MODD), an insulin delivery system technology company preparing to launch a market expansion product with a more accessible, easier to prescribe, and easier to pay for and live with technology, today announced it has received U. S. Food and Drug Administration ("FDA") clearance to market and sell its MODD1 pump in the United States.
Registration is Now Open for Tribe Public's Webinar Event "Diabetes Care Innovator Modular Medical Takes Next Steps" Featuring Modular Medical CEO on Friday, August 9, 2024
The global diabetes care market, valued at $18.9 billion in 2023, is projected to reach $35.8 billion by 2028 The insulin pump segment is expected to grow from $5.26 billion to $21.65 billion by 2032 Discover how Modular Medical is accelerating the development of technology to empower the whole diabetes community with MODD1 Meet with Modular Medical CEO Jeb Besser SAN DIEGO, CA / ACCESSWIRE / August 8, 2024 / Modular Medical, Inc. (NASDAQ:MODD) ("Modular Medical" or the "Company"), a development-stage, insulin delivery technology company seeking to launch the next generation of user-friendly and affordable insulin pump technology, today announced that Jeb Besser, CEO of Modular Medical, will present at Tribe Public's Webinar Presentation and Q&A Event titled "Diabetes Care Innovator Modular Medical Takes Next Steps." The Event is scheduled to begin at 8:30am pacific/11:30am eastern on Friday, August 9, 2024.
Modular Medical Initiates Transfer of Manufacturing Operations to Phillips Medisize
SAN DIEGO, CA / ACCESSWIRE / August 7, 2024 / Modular Medical, Inc. (the "Company" or "Modular Medical") (NASDAQ:MODD), an insulin delivery system technology company preparing to launch the next generation of easy-to-use, prescribe and live with affordable insulin pump technology, today announced it has begun the transfer of its pilot line manufacturing operations to a Phillips Medisize manufacturing site in Queretaro, Mexico. Phillips Medisize, a Molex company, has been an outstanding collaborator in the development of Modular Medical's platform product, supply chain and manufacturing operations, as the Company intends to transition from pre-commercial production to high-volume device manufacturing.
Modular Medical Announces Proof-of-Concept Study for Personalized Metabolic Therapy utilizing the MODD1 Platform
Pre-clinical study to explore use of MODD1 pump as a delivery system for FDA-approved, short acting peptides, as a personalized alternative for people who discontinue long-acting GLP-1 formulations SAN DIEGO, CA / ACCESSWIRE / July 15, 2024 / Modular Medical, Inc. (NASDAQ:MODD) ("Modular Medical" or the "Company"), an insulin delivery technology company seeking to launch the next generation of user-friendly and affordable insulin pump technology, today announced a proof-of-concept study with Gubra A/S ("Gubra") in a high-fat, diet-induced obese ("DIO") mouse model to explore the potential future use of the MODD1 pump platform to assist patients who struggle with tolerability, inconsistent efficacy, and cost of long acting GLP-1 therapies. "A recent study published by Blue Health Intelligence using data from a national dataset of private insurers found that about half of all patients prescribed a GLP-1 drug for weight loss discontinued after the first 12 weeks, with approximately 30% discontinuing in the first four weeks," commented Jeb Besser, Chief Executive Officer of Modular Medical.
